Literature DB >> 17326672

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.

Derek W Bartlett1, Mark E Davis.   

Abstract

Nucleic acid-based therapeutics have the potential to provide potent and highly specific treatments for a variety of human ailments. However, systemic delivery continues to be a significant hurdle to success. Multifunctional nanoparticles are being investigated as systemic, nonviral delivery systems, and here, we describe the physicochemical and biological characterization of cyclodextrin-containing polycations (CDP) and their nanoparticles formed with nucleic acids including plasmid DNA (pDNA) and small interfering RNA (siRNA). These polycation/nucleic acid complexes can be tuned by formulation conditions to yield particles with sizes ranging from 60 to 150 nm, zeta potentials from 10 to 30 mV, and molecular weights from approximately 7 x 107 to 1 x 109 g mol-1 as determined by light scattering techniques. Inclusion complexes formed between adamantane (AD)-containing molecules and the beta-cyclodextrin molecules enable the modular attachment of poly(ethylene glycol) (AD-PEG) conjugates for steric stabilization and targeting ligands (AD-PEG-transferrin) for cell-specific targeting. A 70 nm particle can contain approximately 10 000 CDP polymer chains, approximately 2000 siRNA molecules, approximately 4000 AD-PEG5000 molecules, and approximately 100 AD-PEG5000-Tf molecules; this represents a significant payload of siRNA and a large ratio of siRNA to targeting ligand (20:1). The particles protect the nucleic acid payload from nuclease degradation, do not aggregate at physiological salt concentrations, and cause minimal erythrocyte aggregation and complement fixation at the concentrations typically used for in vivo application. Uptake of the nucleic acid-containing particles by HeLa cells is measured by flow cytometry and visualized by confocal microscopy. Competitive uptake experiments show that the transferrin-targeted particles display enhanced affinity for the transferrin receptor through avidity effects (multiligand binding). Functional efficacy of the delivered pDNA and siRNA is demonstrated through luciferase reporter protein expression and knockdown, respectively. The analysis of the CDP delivery vehicle provides insights that can be applied to the design of targeted nucleic acid delivery vehicles in general.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326672      PMCID: PMC2517011          DOI: 10.1021/bc0603539

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  26 in total

1.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.

Authors:  Siwen Hu-Lieskovan; Jeremy D Heidel; Derek W Bartlett; Mark E Davis; Timothy J Triche
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

2.  Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo.

Authors:  P C Rensen; L A Sliedregt; M Ferns; E Kieviet; S M van Rossenberg; S H van Leeuwen; T J van Berkel; E A Biessen
Journal:  J Biol Chem       Date:  2001-07-30       Impact factor: 5.157

3.  Development of a nonviral gene delivery vehicle for systemic application.

Authors:  Suzie Hwang Pun; Mark E Davis
Journal:  Bioconjug Chem       Date:  2002 May-Jun       Impact factor: 4.774

4.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication.

Authors:  David V Morrissey; Karin Blanchard; Lucinda Shaw; Kristi Jensen; Jennifer A Lockridge; Brent Dickinson; James A McSwiggen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Barry A Polisky; Shawn Zinnen
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

Review 6.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.

Authors:  Daniele Venturoli; Bengt Rippe
Journal:  Am J Physiol Renal Physiol       Date:  2005-04

7.  Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Authors:  Gregory P Adams; Mei-Sheng Tai; John E McCartney; James D Marks; Walter F Stafford; L L Houston; James S Huston; Louis M Weiner
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles.

Authors:  Suzie H Pun; Frederik Tack; Nathalie C Bellocq; Jianjun Cheng; Brendan H Grubbs; Gregory S Jensen; Mark E Davis; Marcus Brewster; Michel Janicot; Boudewijn Janssens; Wim Floren; Annette Bakker
Journal:  Cancer Biol Ther       Date:  2004-07-09       Impact factor: 4.742

9.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.

Authors:  Swaroop Mishra; Paul Webster; Mark E Davis
Journal:  Eur J Cell Biol       Date:  2004-04       Impact factor: 4.492

10.  EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Ernst Wagner; Alexander Levitzki
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

View more
  74 in total

1.  Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Authors:  Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2010-06-10       Impact factor: 12.531

2.  Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

Authors:  Jonathan E Zuckerman; Chung Hang J Choi; Han Han; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 3.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

4.  Structural and functional consequences of poly(ethylene glycol) inclusion on DNA condensation for gene delivery.

Authors:  Peter G Millili; Joshua A Selekman; Kory M Blocker; David A Johnson; Ulhas P Naik; Millicent O Sullivan
Journal:  Microsc Res Tech       Date:  2010-09       Impact factor: 2.769

Review 5.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

6.  Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Nano Today       Date:  2010-08-01       Impact factor: 20.722

Review 7.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

Review 8.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

9.  Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo.

Authors:  Christopher E Nelson; James R Kintzing; Ann Hanna; Joshua M Shannon; Mukesh K Gupta; Craig L Duvall
Journal:  ACS Nano       Date:  2013-09-23       Impact factor: 15.881

10.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Authors:  Derek W Bartlett; Helen Su; Isabel J Hildebrandt; Wolfgang A Weber; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.